Integrated Team Leader, Pipeline/Business Development, I&I/Rare Disease


Successful product access is fundamental to the achievement of Pfizer's commercial objectives in the evolving, complex pharmaceutical payer environment, which must begin in early development. The Rare Disease (RD) and Immunology and Inflammation (I&I) business units within Pfizer have a robust pipeline of products in many therapeutic areas: hematology, cardiology, neuromuscular, metabolic and endocrine (RD) and medical dermatology, rheumatology, and gastroenterology (GI; I&I).

The Integrated Team Leader, Pipeline/Business Development, I&I/Rare Disease, is responsible for development and inclusion of high-quality evidence generation plans and market access strategies into the internal and external development assessments for national-level public payers and private commercial insurers.

This ILT will function with a One PHI mindset and will lead a team of health economics and outcomes research (HEOR) scientists and market access and pricing strategists. She/he will join the I&I PHI LT and RD PHI LT to ensure there is a single and coordinated view on strategy and delivery for PHI, and will collaborate seamlessly with the PHI Centers of Excellence such as RWE CoE, Healthcare Innovation Center, and others. The team lead will become a strategic partner to research, development, regulatory, commercial, medical, prioritized country teams and any alliance partners.

The ITL must have a global business-wide perspective and should adopt a leadership position on strategic questions with respect to the value, access and outcomes required of assets in development and be the "voice of the payer" to internal stakeholders. She/he needs to have a high degree of expertise and employ a patient and payer-centric mindset to work closely in an aligned fashion with various partner and stakeholder groups and innovative approaches for RD and gene therapies in development. This will ensure there is a single and coordinated view on strategy to provide timely delivery of PHI outputs to inform key business decisions. Lastly, the ITL must be able to design, develop and implement an integrated approach to all aspects of the payer value proposition from early development through phase III and across geographies (such as US, EU, Asia) for RD & I&I TAs described above.

  • Lead Team: Lead Pipeline/BD I&I and RD franchise comprised of HEOR scientists, PCOA scientists and market access strategists
    • Execute projects as per Operating Plans or newly identified priorities and manage pipeline budget for those projects
    • Lead and oversee HEOR strategy development and implementation to support brand strategies and product positioning
    • Oversees and approves evidence generation activities, such as: RWD studies of comparative effectiveness and cost; design and implementation of clinical trials with HEOR components; and early economic models, aligned with the overall product strategy
    • Lead development of early economic modeling for population selection and early pricing
    • Able to influence and shape the life cycle management program utilizing individual depth of knowledge and experience in value evidence generation and reimbursement
    • Represent Pfizer's interests in high level interactions with influential bodies (affiliates, international health administration bodies, advocacy groups, specialty associations, etc.)
    • Provide leadership and mentorship development including subject matter expertise as needed
    • Provide relevant input into selection of patient population and comparators within clinical trials to enable demonstration of robust incremental clinical value over standard of care that can facilitate optimal patient access
    • Approve the selection, related analyses, interpretation and communication of Patient Reported Outcomes (PRO) measures as appropriate for assigned clinical trials, registries, and prospective real world studies
  • Enterprise Leadership & Strategic Partnership: Become an leading member of the PHI I&I/RD LTs and a strategic partner to WRD, GPD, Commercial Marketing, Medical, prioritized countries and Regulatory; effectively liaise with PHI's Centers of Excellence
    • Advance functional excellence for Market Access and Health Economics and Outcomes Research
    • Deliver clear recommendations for the overall access and payer strategy, pricing and reimbursement, evidence generation, data collection and value proposition
    • Maintain in-depth understanding of payer regulations, needs of all types of payers (e.g. HTA agencies, institutions and patients) in key Pfizer markets, and lead horizon-scanning to ensure evolving payer expectations are integrated into strategies and recommendations.
    • Lead assessment and communication of external access trends to anticipate potential challenges and opportunities for pipeline & inline portfolio.
    • Gather and synthesize feedback for development programs with health technology assessment agencies, payers, and relevant patient associations
    • Develop clear and cohesive access, pricing and evidence generation strategy to optimize value of pipeline & BD programs and overall portfolio.
    • Lead discussions with Country Health & Value and Payer Channel Access Leads at critical junctures to ensure local insights are integrated into global plans that optimize long-term value for our programs/portfolio, including input into clinical development plans, market access and pricing strategies and recommendations, early HTA advice, early economic models, and evidence generation plans via the Value & Access Plan.
    • Lead alignment efforts with Commercial, BAI, Clinical, Medical, Asset and BD teams to ensure clinical trial design and commercial strategies reflect payer insights and align with Bold Moves in order to maximize value of the program.
    • Lead discussions and seek early buy-in from senior leadership on price and market access strategy and recommendations to support key business decision points.
    • Drive development of the early value proposition and value-based agreement strategy and seek buy-in from cross-functional stakeholders
    • Lead appropriate data dissemination plans and communicate in a timely manner evidence generated to various stakeholders via publications and conference presentations
  • Best in Class Assessments: Provide PHI viewpoint on internal assessments or Business Development opportunities across RD & I&I
    • Provide strategic guidance in partnership with BD teams on optimal pricing and access strategies for BD deals;
    • Conduct rapid payer research to assess pricing potential of products across RD or I&I


Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
  • PhD in relevant discipline (health services research, epidemiology, health economics, psychology, etc.) with 10+ years of work experience in the conduct of outcomes research to evaluate health care interventions.
  • Or a Master's degree in relevant discipline with 13+ years of pharmaceutical research experience in several therapeutic areas evaluating health care interventions with 5+ years of that research experience conducting health economics, health related quality of life and epidemiology studies in the pharmaceutical industry.
  • Knowledge and experience in early drug development. Strong technical knowledge of health economics and pricing/access
  • Experienced in leading a team with strong track record of high level of engagement and delivering results
  • Strong working knowledge of the technical and methodological aspects of registries and observational study design and implementation preferred.
  • Strong methodological skills (study design, data analysis and interpretation) in clinical trials, epidemiology, or health services research preferred
  • In depth understanding of pharmacoeconomics, health-related Quality of Life and / or pricing and access dynamics preferred
  • Experience with Rare Disease/I&I medicines is a plus
  • Very good working knowledge of US pricing and access dynamics
  • Experience with HTA organizations such as NICE, SMC, PBAC is desirable
  • Excellent interpersonal skills required: ability to understand and respond to multiple internal and external customers; build strategic partnerships internally and externally
  • Excellent oral and written English communication skills required
  • Strong project management abilities (contracting, budgeting, vendor management) essential.
  • Demonstrated ability to manage multiple projects (multitask) involving complex processes, significant budget, competing deadlines and rapidly shifting priorities
  • Ability to influence key members of scientific and commercial teams constructively and without conflict
  • Leadership in studies that involve evidence generation, specifically related to RWE, NIS studies for access and delivering payer value
  • Skilled in functioning within a matrix organization where managing through influence is required

Other Job Details:

Last Date to Apply for Job: September 28th, 2021

Additional Location Information: New York, NY; Collegeville, PA; Europe - Remote; US - Remote; North America - Remote


Pfizer requires all U.S. new hires to be fully vaccinated for COVID-19 prior to the first date of employment. As required by applicable law, Pfizer will consider requests for Reasonable Accommodations.

Sunshine Act

Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.

EEO & Employment Eligibility

Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.

Market Access